Search research articles
Contact Us
Filters
Showing results (51-60 of 54) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 54 results.
Blood Advances
|
August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
Jennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Blood
|
June 11, 2026
Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma
Jerald D Noble, Barbara C Peixoto, Meghan A Menges, et al.
Transplantation and Cellular Therapy
|
July 23, 2023
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis
Brandon J Blue, Ruta Brazauskas, Karen Chen, et al.
Blood Cancer Journal
|
March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium
Andrew J Portuguese, James A Davis, Shahzad Raza, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 54) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 54 results.
Blood Advances
|
August 8, 2022
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
Jennifer M Logue, Lauren C Peres, Hamza Hashmi, et al.
Blood
|
June 11, 2026
Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma
Jerald D Noble, Barbara C Peixoto, Meghan A Menges, et al.
Transplantation and Cellular Therapy
|
July 23, 2023
Racial and Socioeconomic Disparities in Long-Term Outcomes in ≥1 Year Allogeneic Hematopoietic Cell Transplantation Survivors: A CIBMTR Analysis
Brandon J Blue, Ruta Brazauskas, Karen Chen, et al.
Blood Cancer Journal
|
March 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium
Andrew J Portuguese, James A Davis, Shahzad Raza, et al.
Page
of 6